Key result
Biweekly CAPOX reduced the incidence of all-grade thrombocytopenia compared to triweekly CAPOX in patients with resected high-risk stage II and stage III colorectal cancer.
Why the study?
The study was conducted to compare the safety and efficiency of modified biweekly CAPOX versus conventional triweekly CAPOX in high-risk stage II and stage III post-surgery colorectal cancer patients.
Does biweekly CAPOX reduce the incidence of thrombocytopenia compared to triweekly CAPOX in high-risk stage II and stage III post-surgery colorectal cancer patients?
RCT (n=160)
Open-label
1:1 blocked randomization
No
Does biweekly CAPOX reduce the incidence of thrombocytopenia compared to triweekly CAPOX in high-risk stage II and stage III post-surgery colorectal cancer patients?
Answers are grounded in this paper and cite their sources.
In patients with high-risk stage II and stage III colorectal cancer, a modified biweekly CAPOX regimen significantly reduced the incidence of thrombocytopenia and neutropenia compared to the conventional triweekly regimen, without compromising 3-year disease-free survival.
PURPOSE: This study aims to compare the safety and efficiency of modified biweekly CAPOX and conventional triweekly CAPOX in high-risk stage II and stage III post-surgery colorectal (CRC) patients. METHODS: From July 25, 2018, to May 14, 2021, high-risk stage II and stage III post-surgery CRC patients were randomized in the control triweekly group (intravenous infusion of oxaliplatin 130 mg/m2 on day 1 and oral capecitabine 1000 mg/m2, twice daily from day 1 to day 14) and the experimental biweekly group (intravenous infusion of oxaliplatin 85 mg/m2 on day 1 and oral capecitabine 1000 mg/m2, twice daily from day 1 to day 10). The primary endpoint was the incidence rate of thrombocytopenia. The secondary endpoint was 3-year disease free survival (DFS) rate. The patients follow up was started on July 25, 2018, and finished on October 8, 2024. RESULTS: A total of 160 patients were 1:1 randomly assigned (80 patients to biweekly group and 80 patients to triweekly group). All grade thrombocytopenia occurred in 33% and 49% patients at biweekly and triweekly group, respectively (P = 0.02). Neutropenia presented in 36% and 51% patients at biweekly and triweekly group, respectively (P = 0.04). The second endpoint 3-year DFS was 85.1% in biweekly group and 80.4% in triweekly CAPOX group (P = 0.51, HR = 0.78, [95%CI, 0.38-1.63]). The total rate of uncomplete therapy patient was 7.5% and 15% in biweekly and triweekly group, respectively (P = 0.13). CONCLUSION: Biweekly CAPOX presented significant less thrombocytopenia and neutropenia than triweekly CAPOX regimen. There was no difference in 3-year DFS between biweekly CAPOX and triweekly CAPOX. Clinical trial registration: ClinicalTials.gov (NCT03564912).
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) conducted an RCT in High-risk stage II and stage III post-surgery colorectal cancer (n=160). Biweekly CAPOX vs. Triweekly CAPOX was evaluated on Incidence rate of all-grade thrombocytopenia (p=0.02). Biweekly CAPOX reduced the incidence of all-grade thrombocytopenia compared to triweekly CAPOX in patients with resected high-risk stage II and stage III colorectal cancer.
Synapse has enriched 10 related papers. Consider them for comparative context: